Skip to main content
Top
Published in: Advances in Therapy 6/2024

Open Access 25-04-2024 | Chronic Obstructive Lung Disease | Review

Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review

Authors: Dave Singh, MeiLan K. Han, Nathaniel M. Hawkins, John R. Hurst, Janwillem W. H. Kocks, Neil Skolnik, Daiana Stolz, Jad El Khoury, Chris P. Gale

Published in: Advances in Therapy | Issue 6/2024

Login to get access

Abstract

Chronic obstructive pulmonary disease (COPD) constitutes a major global health burden and is the third leading cause of death worldwide. A high proportion of patients with COPD have cardiovascular disease, but there is also evidence that COPD is a risk factor for adverse outcomes in cardiovascular disease. Patients with COPD frequently die of respiratory and cardiovascular causes, yet the identification and management of cardiopulmonary risk remain suboptimal owing to limited awareness and clinical intervention. Acute exacerbations punctuate the progression of COPD in many patients, reducing lung function and increasing the risk of subsequent exacerbations and cardiovascular events that may lead to early death. This narrative review defines and summarises the principles of COPD-associated cardiopulmonary risk, and examines respiratory interventions currently available to modify this risk, as well as providing expert opinion on future approaches to addressing cardiopulmonary risk.
Literature
32.
go back to reference Vogelmeier C, Simons S, Garbe E, Sin D, Hawkins N, Manito N, et al. Increased risk of severe cardiovascular events following exacerbations of COPD: a multi-database cohort study. Eur Respir J 2023;62:PA3013 (Abstract). Vogelmeier C, Simons S, Garbe E, Sin D, Hawkins N, Manito N, et al. Increased risk of severe cardiovascular events following exacerbations of COPD: a multi-database cohort study. Eur Respir J 2023;62:PA3013 (Abstract).
34.
go back to reference Dransfield MT, Criner GJ, Halpin, Han MK, Hartley B, Kalhan R, et al. Time‐dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J Am Heart Assoc 2022;11:e024350. https://doi.org/10.1161/JAHA.121.024350. Dransfield MT, Criner GJ, Halpin, Han MK, Hartley B, Kalhan R, et al. Time‐dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J Am Heart Assoc 2022;11:e024350. https://​doi.​org/​10.​1161/​JAHA.​121.​024350.
44.
go back to reference Rapsomaniki E, Müllerová H, Hughes R, Marshall J, Papi A, Reddel H, et al. Frequent productive cough associates with an increased risk of cardiopulmonary outcomes in a real-life cohort of patients with COPD (NOVELTY study). Eur Respir J. 2023;62(Suppl. 67):PA1928 (Abstract). Rapsomaniki E, Müllerová H, Hughes R, Marshall J, Papi A, Reddel H, et al. Frequent productive cough associates with an increased risk of cardiopulmonary outcomes in a real-life cohort of patients with COPD (NOVELTY study). Eur Respir J. 2023;62(Suppl. 67):PA1928 (Abstract).
57.
go back to reference Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747–58. https://doi.org/10.1016/S2213-2600(18)30327-8.CrossRefPubMed Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747–58. https://​doi.​org/​10.​1016/​S2213-2600(18)30327-8.CrossRefPubMed
58.
59.
go back to reference Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–73. https://doi.org/10.1016/S0140-6736(16)31354-X.CrossRefPubMed Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–73. https://​doi.​org/​10.​1016/​S0140-6736(16)31354-X.CrossRefPubMed
63.
go back to reference Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: a post hoc analysis of data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022;17:3061–73. https://doi.org/10.2147/COPD.S374670.CrossRefPubMedPubMedCentral Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: a post hoc analysis of data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022;17:3061–73. https://​doi.​org/​10.​2147/​COPD.​S374670.CrossRefPubMedPubMedCentral
67.
go back to reference Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann H-C, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6:368–78. https://doi.org/10.1016/S2213-2600(18)30054-7.CrossRefPubMed Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann H-C, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6:368–78. https://​doi.​org/​10.​1016/​S2213-2600(18)30054-7.CrossRefPubMed
70.
go back to reference Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD: a randomized, double-blind, multi-center, parallel-group study. Am J Respir Crit Care Med. 2020;203:553–64. https://doi.org/10.1164/rccm.202006-2618OC.CrossRef Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD: a randomized, double-blind, multi-center, parallel-group study. Am J Respir Crit Care Med. 2020;203:553–64. https://​doi.​org/​10.​1164/​rccm.​202006-2618OC.CrossRef
75.
go back to reference Stolz D, Cazzola M. Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists. In: Martínez-García MÁ, Pépin J-L, Cazzola M, editors. Cardiovascular complications of respiratory disorders. Sheffield: European Respiratory Society; 2020. p. 238–50. https://doi.org/10.1183/2312508X.10028619.CrossRef Stolz D, Cazzola M. Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists. In: Martínez-García MÁ, Pépin J-L, Cazzola M, editors. Cardiovascular complications of respiratory disorders. Sheffield: European Respiratory Society; 2020. p. 238–50. https://​doi.​org/​10.​1183/​2312508X.​10028619.CrossRef
81.
go back to reference Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.CrossRefPubMed Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.CrossRefPubMed
85.
go back to reference García-Río F. Lung hyperinflation in chronic obstructive pulmonary disease: clinical and therapeutic relevance. BRN Rev. 2020;6:67–86. García-Río F. Lung hyperinflation in chronic obstructive pulmonary disease: clinical and therapeutic relevance. BRN Rev. 2020;6:67–86.
86.
go back to reference Hwang HJ, Lee SM, Seo JB, Lee JS, Kim N, Kim C, et al. Assessment of changes in regional xenon-ventilation, perfusion, and ventilation-perfusion mismatch using dual-energy computed tomography after pharmacological treatment in patients with chronic obstructive pulmonary disease: visual and quantitative analysis. Int J Chron Obstruct Pulmon Dis. 2019;14:2195–203. https://doi.org/10.2147/COPD.S210555.CrossRefPubMedPubMedCentral Hwang HJ, Lee SM, Seo JB, Lee JS, Kim N, Kim C, et al. Assessment of changes in regional xenon-ventilation, perfusion, and ventilation-perfusion mismatch using dual-energy computed tomography after pharmacological treatment in patients with chronic obstructive pulmonary disease: visual and quantitative analysis. Int J Chron Obstruct Pulmon Dis. 2019;14:2195–203. https://​doi.​org/​10.​2147/​COPD.​S210555.CrossRefPubMedPubMedCentral
Metadata
Title
Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review
Authors
Dave Singh
MeiLan K. Han
Nathaniel M. Hawkins
John R. Hurst
Janwillem W. H. Kocks
Neil Skolnik
Daiana Stolz
Jad El Khoury
Chris P. Gale
Publication date
25-04-2024
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 6/2024
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-024-02855-4

Other articles of this Issue 6/2024

Advances in Therapy 6/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare